Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The evidence base surrounding the clinical use of semaglutide is being further expanded with trials investigating effects on diabetic retinopathy, cardiovascular outcomes, and on the common T2D comorbidities of obesity, chronic kidney disease, and non-alcoholic steatohepatitis
Procurement teams should evaluate which concentration aligns with their formulation targets, dosage form constraints, and cost-in-use calculations
In the SUSTAIN clinical trial program evaluating subcutaneous semaglutide for type 2 diabetes, once-weekly dosing (0.5 mg or 1.0 mg) reduced HbA1c by 1.5% to 1.8% from baseline, with superior glycemic control compared to specific comparators in head-to-head trials (SUSTAIN-7 vs dulaglutide
Urology (2015)
